Previous 10 | Next 10 |
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results PR Newswire Quarterly EsoGuard ® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall PR Newswire EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck ® unaffected by recall and remains the gold standa...
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors PR Newswire Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President ...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or...
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing PR Newswire EsoGuard demonstrated unprecedented early precancer de...
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month PR Newswire NEW YORK , April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commer...
2024-04-19 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Let’s just get something straight off the bat – penny stocks to rebound are risky. They’re incredibly treacherous in terms of both short-term downside and longer-term d...
2024-04-08 09:00:06 ET Mark Massaro from BTIG issued a price target of $2.50 for LUCD on 2024-04-08 07:51:00. The adjusted price target was set to $2.50. At the time of the announcement, LUCD was trading at $0.9277. The overall price target consensus is at $3.30 with hig...
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK , April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...